Ben Venue Laboratories, based in Bedford, OH, is ceasing all operations of its generic sterile injectables business by the end of 2013. The company has had ongoing support from the FDA for the production of Johnson & Johnson’s cancer drug Doxil, which has suffered shortages, and invested more than $350 million in facility upgrades, but maintains it is unable to sustain production. The closure impacts all of Ben Venue’s 1,100 employees. Interim controls were effectively put in place to...